This company has been marked as potentially delisted and may not be actively trading. NASDAQ:JUNO Juno Therapeutics (JUNO) Stock Price, News & Analysis Add Share Share Stock Analysis Stock AnalysisBuy This Stock About Juno Therapeutics Stock (NASDAQ:JUNO) 30 days 90 days 365 days Advanced Chart Get Juno Therapeutics alerts:Sign Up Key Stats Today's Range$86.96▼$86.9650-Day Range$86.96▼$86.9652-Week Range$19.62▼$87.01Volume2 shsAverage Volume5.48 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity. Read More Receive JUNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Juno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JUNO Stock News HeadlinesCancer research foundation to start seeding startupsJune 11, 2025 | msn.comThe Pediatric Brain Tumor Foundation welcomes Day One Biopharmaceuticals’ renowned Dr. Samuel C. Blackman to its Board of DirectorsJanuary 30, 2025 | markets.businessinsider.comLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, and the deadline is fast-approaching. A new federal plan could legally unlock $100 trillion in U.S. resources... and one $10 stock could lead the charge. Former hedge fund manager Whitney Tilson explains how to act now, before this hits the headlines. | Stansberry Research (Ad)Eterna Therapeutics Announces Expansion of Scientific Advisory BoardJanuary 28, 2025 | markets.businessinsider.comEterna Therapeutics expands scientific board with oncology expertsJanuary 28, 2025 | msn.comSeattle biotech company raises the first local 9-figure round of 2025January 13, 2025 | bizjournals.comSeattle biotech startup Tune Therapeutics lands $175M to support clinical researchJanuary 13, 2025 | msn.comCAR-T Cell Therapy Market Research 2024-2025: Navigating the CAR-T Landscape, Major Players, Recent Approvals, and Pioneering TherapiesJanuary 3, 2025 | finance.yahoo.comSee More Headlines JUNO Stock Analysis - Frequently Asked Questions How were Juno Therapeutics' earnings last quarter? Juno Therapeutics Inc (NASDAQ:JUNO) released its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.07. The firm's revenue for the quarter was up 115.4% on a year-over-year basis. When did Juno Therapeutics IPO? Juno Therapeutics (JUNO) raised $153 million in an IPO on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Leerink Partners was co-manager. What other stocks do shareholders of Juno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Juno Therapeutics investors own include Bristol Myers Squibb (BMY), (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Meta Platforms (META), Puma Biotechnology (PBYI) and BioMarin Pharmaceutical (BMRN). Company Calendar Last Earnings11/01/2017Today8/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:JUNO CIK1594864 Webwww.junotherapeutics.com Phone+1-206-5821600FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:JUNO) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Juno Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Juno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.